Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Oppenheimer

Oppenheimer initiated coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a report published on Monday, Marketbeat.com reports. The brokerage issued an outperform rating and a $34.00 target price on the stock.

Several other equities research analysts have also weighed in on the company. Piper Sandler dropped their target price on Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. Evercore ISI began coverage on Dyne Therapeutics in a report on Thursday, May 29th. They set an “outperform” rating and a $46.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target for the company. HC Wainwright cut their price objective on Dyne Therapeutics from $46.00 to $38.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Scotiabank initiated coverage on shares of Dyne Therapeutics in a report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $45.54.

Dyne Therapeutics Price Performance

Shares of DYN stock opened at $13.41 on Monday. The firm has a fifty day moving average of $10.40 and a two-hundred day moving average of $15.96. The firm has a market cap of $1.52 billion, a P/E ratio of -3.77 and a beta of 1.19. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, sell-side analysts expect that Dyne Therapeutics will post -3.44 EPS for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

Large investors have recently made changes to their positions in the business. Barclays PLC grew its position in Dyne Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 207,309 shares of the company’s stock valued at $7,446,000 after purchasing an additional 128,246 shares in the last quarter. KBC Group NV boosted its stake in shares of Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in shares of Dyne Therapeutics by 11.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 21,575 shares of the company’s stock valued at $508,000 after acquiring an additional 2,265 shares in the last quarter. abrdn plc purchased a new position in shares of Dyne Therapeutics during the 4th quarter valued at $608,000. Finally, Legato Capital Management LLC acquired a new position in shares of Dyne Therapeutics in the fourth quarter worth $305,000. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.